Assembly Biosciences Inc (ASMB) - Total Assets
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) holds total assets worth $330.83 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Assembly Biosciences Inc - Total Assets Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see ASMB company net worth for the company's overall valuation and market capitalisation.
Assembly Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Assembly Biosciences Inc's total assets of $330.83 Million consist of 98.8% current assets and 1.2% non-current assets. Review Assembly Biosciences Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $974.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ASMB live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Assembly Biosciences Inc's current assets represent 98.8% of total assets in 2025, an increase from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 1.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Assembly Biosciences Inc Competitors by Total Assets
Key competitors of Assembly Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Assembly Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.99 | 1.64 | 12.61 |
| Quick Ratio | 13.99 | 1.64 | 12.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $304.53 Million | $30.18 Million | $173.29 Million |
Assembly Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Assembly Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.19 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | 116.2% |
| Total Assets | $257.59 Million |
| Market Capitalization | $518.79 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Assembly Biosciences Inc's assets at a significant premium (2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Assembly Biosciences Inc's assets grew by 116.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Assembly Biosciences Inc (2008–2025)
The table below shows the annual total assets of Assembly Biosciences Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $257.59 Million | +116.16% |
| 2024-12-31 | $119.17 Million | -12.90% |
| 2023-12-31 | $136.82 Million | +34.41% |
| 2022-12-31 | $101.79 Million | -46.72% |
| 2021-12-31 | $191.06 Million | -32.55% |
| 2020-12-31 | $283.25 Million | -18.58% |
| 2019-12-31 | $347.89 Million | +29.79% |
| 2018-12-31 | $268.05 Million | +58.32% |
| 2017-12-31 | $169.30 Million | +72.55% |
| 2016-12-31 | $98.12 Million | -26.64% |
| 2015-12-31 | $133.74 Million | +87.78% |
| 2014-12-31 | $71.23 Million | +162.51% |
| 2013-12-31 | $27.13 Million | +31.99% |
| 2012-12-31 | $20.56 Million | -44.51% |
| 2011-12-31 | $37.05 Million | +153.45% |
| 2010-12-31 | $14.62 Million | +8691.73% |
| 2009-12-31 | $166.25K | -80.90% |
| 2008-12-31 | $870.39K | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more